: Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent therapy lines in the era of immunotherapy (ReSeq study)
Laufzeit: 01.01.2022 - 31.12.2025
imported
Kurzfassung
Beschreibung: The objective is to investigate, if primary resistance to 1st line TKI monotherapy predicts response to ICI in subsequent therapy lines and impacts overall survival (OS) in metastatic renal cell carcinoma.
